Creative Planning Supernus Pharmaceuticals, Inc. Transaction History

Creative Planning

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$27.11 - $35.17 $180,877 - $234,654	6,672 New	6,672 $227,000
Q3 2023 Nov 16, 2023	BUY	$27.57 - $32.91 $3,528 - $4,212	128 New	128 $3,000
Q3 2019 Nov 01, 2019	SELL	$25.47 - $33.37 $438,797 - $574,898	-17,228 Closed	0 $0
Q2 2019 Jul 26, 2019	BUY	$29.96 - $38.87 $113,907 - $147,783	3,802 Added 28.32%	17,228 $570,000
Q1 2019 Apr 24, 2019	BUY	$32.77 - $41.99 $150,807 - $193,237	4,602 Added 52.15%	13,426 $470,000
Q4 2018 Feb 01, 2019	SELL	$30.84 - $49.51 $365,885 - $587,386	-11,864 Reduced 57.35%	8,824 $293,000
Q3 2018 Oct 25, 2018	SELL	$42.7 - $56.55 $1,323 - $1,753	-31 Reduced 0.15%	20,688 $1.04 Million
Q2 2018 Jul 20, 2018	BUY	$44.1 - $59.85 $194,701 - $264,237	4,415 Added 27.08%	20,719 $1.24 Million
Q1 2018 Apr 18, 2018	SELL	$37.15 - $46.9 $214,504 - $270,800	-5,774 Reduced 26.15%	16,304 $747,000
Q4 2017 Jan 17, 2018	SELL	$36.4 - $42.6 $107,598 - $125,925	-2,956 Reduced 11.81%	22,078 $880,000
Q3 2017 Oct 17, 2017	BUY	$36.75 - $49.65 $919,999 - $1.24 Million	25,034	25,034 $1 Million

283

60.6M

27.7K

11.3K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $2.06B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of Creative Planning, based on Form 13F filings with the SEC.

Stay updated on Creative Planning with notifications on news.